User login
Image by Lance Liotta
Two genes can stop the development of acute myeloid leukemia (AML), according to research published in the Journal of Experimental Medicine.
The work suggests that Hif-1α and Hif-2α work together to stop the formation of leukemic stem cells, and blocking either Hif-2α or both genes
accelerates AML development.
Investigators said these findings are surprising because previous research suggested that blocking Hif-1α or Hif-2α might stop AML progression.
But their study suggests that therapies designed to block these genes might worsen AML or at least have no impact on the disease.
Conversely, designing new therapies that promote the activity of Hif-1α and Hif-2α could help treat AML or stop relapse after chemotherapy.
“Our discovery that Hif-1α and Hif-2α molecules act together to stop leukemia development is a major milestone in our efforts to combat leukemia,” said study author Kamil R. Kranc, DPhil, of the University of Edinburgh in Scotland.
“We now intend to harness this knowledge to develop curative therapies that eliminate leukemic stem cells, which are the underlying cause of AML.” 
Image by Lance Liotta
Two genes can stop the development of acute myeloid leukemia (AML), according to research published in the Journal of Experimental Medicine.
The work suggests that Hif-1α and Hif-2α work together to stop the formation of leukemic stem cells, and blocking either Hif-2α or both genes
accelerates AML development.
Investigators said these findings are surprising because previous research suggested that blocking Hif-1α or Hif-2α might stop AML progression.
But their study suggests that therapies designed to block these genes might worsen AML or at least have no impact on the disease.
Conversely, designing new therapies that promote the activity of Hif-1α and Hif-2α could help treat AML or stop relapse after chemotherapy.
“Our discovery that Hif-1α and Hif-2α molecules act together to stop leukemia development is a major milestone in our efforts to combat leukemia,” said study author Kamil R. Kranc, DPhil, of the University of Edinburgh in Scotland.
“We now intend to harness this knowledge to develop curative therapies that eliminate leukemic stem cells, which are the underlying cause of AML.”
Image by Lance Liotta
Two genes can stop the development of acute myeloid leukemia (AML), according to research published in the Journal of Experimental Medicine.
The work suggests that Hif-1α and Hif-2α work together to stop the formation of leukemic stem cells, and blocking either Hif-2α or both genes
accelerates AML development.
Investigators said these findings are surprising because previous research suggested that blocking Hif-1α or Hif-2α might stop AML progression.
But their study suggests that therapies designed to block these genes might worsen AML or at least have no impact on the disease.
Conversely, designing new therapies that promote the activity of Hif-1α and Hif-2α could help treat AML or stop relapse after chemotherapy.
“Our discovery that Hif-1α and Hif-2α molecules act together to stop leukemia development is a major milestone in our efforts to combat leukemia,” said study author Kamil R. Kranc, DPhil, of the University of Edinburgh in Scotland.
“We now intend to harness this knowledge to develop curative therapies that eliminate leukemic stem cells, which are the underlying cause of AML.”